Profound Medical Corp.

TSX:PRN 주식 보고서

시가총액: CA$286.9m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Profound Medical 관리

관리 기준 확인 3/4

Profound Medical's CEO는 Arun Menawat, Aug2016 에 임명되었습니다 의 임기는 7.83 년입니다. 총 연간 보상은 $ 889.95K, 41.6% 로 구성됩니다. 41.6% 급여 및 58.4% 보너스(회사 주식 및 옵션 포함). 는 CA$ 5.55M 가치에 해당하는 회사 주식의 1.89% 직접 소유합니다. 5.55M. 경영진과 이사회의 평균 재임 기간은 각각 2.1 년과 4.8 년입니다.

주요 정보

Arun Menawat

최고 경영자

US$889.9k

총 보상

CEO 급여 비율41.6%
CEO 임기7.8yrs
CEO 소유권1.9%
경영진 평균 재임 기간1.8yrs
이사회 평균 재임 기간4.8yrs

최근 관리 업데이트

Recent updates

Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet?

May 03
Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet?

Is Profound Medical (TSE:PRN) Using Debt In A Risky Way?

Sep 15
Is Profound Medical (TSE:PRN) Using Debt In A Risky Way?

Will Profound Medical (TSE:PRN) Spend Its Cash Wisely?

Sep 07
Will Profound Medical (TSE:PRN) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation

Jan 07
Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation

We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth

Jul 02
We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth

We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned

May 13
We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned

Analysts Expect Breakeven For Profound Medical Corp. (TSE:PRN) Before Long

May 07
Analysts Expect Breakeven For Profound Medical Corp. (TSE:PRN) Before Long

We Think Profound Medical (TSE:PRN) Can Afford To Drive Business Growth

Mar 25
We Think Profound Medical (TSE:PRN) Can Afford To Drive Business Growth

How Many Profound Medical Corp. (TSE:PRN) Shares Do Institutions Own?

Mar 04
How Many Profound Medical Corp. (TSE:PRN) Shares Do Institutions Own?

Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future

Jan 27
Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future

CEO 보상 분석

Arun Menawat 의 보수는 Profound Medical 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$890kUS$370k

-US$29m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$916kUS$344k

-US$29m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$4mUS$481k

-US$31m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$2mUS$1m

-US$22m

Sep 30 2020n/an/a

-US$18m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$2mUS$531k

-US$15m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019n/an/a

-US$14m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$672kUS$509k

-US$15m

Sep 30 2018n/an/a

-US$16m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$264kUS$264k

-US$15m

보상 대 시장: Arun 의 총 보상 ($USD 889.95K )은 Canadian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 779.82K ).

보상과 수익: Arun 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Arun Menawat (69 yo)

7.8yrs

테뉴어

US$889,948

보상

Dr. Arun Swarup Menawat, Ph D., MBA, served as the Chairman at Firefly Neuroscience, Inc. and is its Director. He serves as the Chairman at Profound Medical Corp. Dr. Menawat has been the Chief Executive O...

리더십 팀

이름위치테뉴어보상소유권
Arun Menawat
Chairman of the Board & CEO7.8yrsUS$889.95k1.89%
$ 5.4m
Rashed Dewan
Chief Financial Officer3.1yrsUS$669.26k0.097%
$ 278.3k
Mathieu Burtnyk
Chief Operating Officerless than a yearUS$396.81k0.055%
$ 158.8k
Hartmut Warnken
Senior Vice President for Strategic Alliances1.8yrsUS$226.17k0.0039%
$ 11.1k
Abbey Goodman
Chief Commercial Officer of Global1.8yrsUS$555.98k0%
$ 0
Stephen Kilmer
Investor Relationsno data데이터 없음데이터 없음
Jacques Cornet
VP of International Sales & Marketingno data데이터 없음데이터 없음
Matthew Sobczyk
Assistant Corporate Controllerno data데이터 없음데이터 없음
Levant Tinaz
Software Developerno data데이터 없음데이터 없음

1.8yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: PRN 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
Arun Menawat
Chairman of the Board & CEO9yrsUS$889.95k1.89%
$ 5.4m
Arthur L. Rosenthal
Independent Director6yrsUS$101.96k0.071%
$ 202.8k
Brian Ellacott
Independent Lead Director6yrsUS$102.91k0.28%
$ 797.0k
Cynthia Lavoie
Independent Director3.3yrsUS$97.91k0.025%
$ 70.3k
Mark Emberton
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Murielle Lortie
Independent Director3.6yrsUS$100.41k0.013%
$ 36.9k
Eric Klein
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Laurence Klotz
Member of Clinical Advisory Board1.7yrs데이터 없음데이터 없음
Scott Eggener
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Adam Kibel
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Aytekin Oto
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Ian Thompson
Member of Clinical Advisory Boardno data데이터 없음데이터 없음

4.8yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: PRN 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.